CGL
BEAM icon

Clarius Group LLC’s Beam Therapeutics BEAM Stock Holding History

Clarius Group LLC’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$1.68M Hold
60,615
– – 0.1% 84
2025
Q3 		$1.47M Hold
60,615
– – 0.09% 95
2025
Q2 		$1.03M Hold
60,615
– – 0.06% 143
2025
Q1 		$1.18M Hold
60,615
– – 0.07% 125
2024
Q4 		$1.5M Hold
60,615
– – 0.1% 91
2024
Q3 		$1.49M Hold
60,615
– – 0.1% 90
2024
Q2 		$1.42M Hold
60,615
– – 0.1% 92
2024
Q1 		$2M Hold
60,615
– – 0.14% 71
2023
Q4 		$1.65M Hold
60,615
– – 0.14% 88
2023
Q3 		$1.46M Hold
60,615
– – 0.14% 84
2023
Q2 		$1.94M Hold
60,615
– – 0.15% 73
2023
Q1 		$1.86M Buy
60,615
+32,504
+116% +$1.28M 0.16% 70
2022
Q4 		$1.1M Hold
28,111
– – 0.1% 124
2022
Q3 		$1.34M Hold
28,111
– – 0.13% 94
2022
Q2 		$1.09M Buy
28,111
+25,421
+945% +$1.01M 0.11% 118
2022
Q1 		$214K Hold
2,690
– – 0.02% 458
2021
Q4 		$214K Sell
2,690
-40
-1% -$3.42K 0.02% 458
2021
Q3 		$238K Buy
2,730
+775
+40% +$77.9K 0.02% 372
2021
Q2 		$252K Buy
+1,955
New +$156K 0.02% 348

Other funds holding BEAM

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Clarius Group LLC's BEAM Position: Q4 2025 in Review

Clarius Group LLC held its Beam Therapeutics (BEAM) position steady in Q4 2025 at 60,615 shares worth $1.68M. The position accounts for 0.1% of the portfolio, ranked #84.

Clarius Group LLC first reported a position in BEAM in Q2 2021 and has held it in 19 quarters since. The position peaked at $2M in Q1 2024. 246 funds tracked by Wall St. Rank hold BEAM as of Q4 2025.

  • Clarius Group LLC held 60,615 shares of Beam Therapeutics worth $1.68M as of Q4 2025.
  • Clarius Group LLC left its Beam Therapeutics share count unchanged in Q4 2025.
  • Beam Therapeutics made up 0.1% of Clarius Group LLC's portfolio in Q4 2025, its #84 holding.
  • Clarius Group LLC first reported a position in Beam Therapeutics in Q2 2021 and has held it in 19 quarters since.
  • Clarius Group LLC's Beam Therapeutics position peaked at $2M in Q1 2024.
  • 246 funds tracked by Wall St. Rank held Beam Therapeutics as of Q4 2025.

Based on Clarius Group LLC's 13F filing for Q4 2025, filed 14 Jan 2026.